GSK Study Shows Tykerb/Herceptin Combo Increases Progression-Free Survival In Breast Cancer
Firm unveils positive Phase III data in women with HER-2 positive metastatic breast cancer weeks ahead of ASCO annual meeting.
Firm unveils positive Phase III data in women with HER-2 positive metastatic breast cancer weeks ahead of ASCO annual meeting.